474.35
+10.22%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gufic Biosciences
Its shares trade on NSE under the ticker GUFICBIO.NS. It has been listed since 19 October 2004. In the fiscal year to 31 March 2025, it reported revenue of ₹8.20bn and net income of ₹696.5m. At that date it held total assets of ₹11.69bn and shareholders' equity of ₹6.01bn.
Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-10-19. The firm operates through the Pharmaceutical segment. The company has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Oct 2004
- Employees
- 1,628
- Website
- gufic.com ↗
Leadership
Pay as last reported
- Mr. Jayesh ChoksiExecutive Chairman of the Board, Managing Director, since 2017₹4.0m
- Mr. Pranav ChoksiChief Executive Officer, Whole Time Director, since 2010₹2.0m
- Mr. Devkinandan RoonghtaChief Financial Officer
- Ms. Ami ShahCompliance Officer, Company Secretary
- Mr. Pankaj GandhiWhole Time Director, since 2013₹1.4m
- Dr. Anu AuroraNon-Executive Independent Director₹70,000
- Mr. Akshya Kumar MahapatraNon-Executive Independent Director
- Mr. Kamal SethAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gufic Biosciences employs 1628 full-time staff members in Mumbai.
- The company markets Criti Care products like Doxific and Micafung.
- API offerings include Micafungin, Anidulafungin, Sulconazole, and Everolimus.
Weaknesses
- The firm operates solely through the Pharmaceutical segment.
- Personal care items like StretchNil lack broader diversification.
- Herbal products such as Bocomo-Forte are niche offerings.
Opportunities
- Expanding Ferticare products like Puregraf and Cetrocare globally.
- Increasing demand for generic pharmaceuticals in emerging markets.
- Growth in active pharmaceutical ingredient manufacturing capabilities.
Threats
- Intense competition in the generic pharmaceuticals market.
- Regulatory changes affecting active pharmaceutical ingredient production.
- Price pressures on bulk drugs like Everolimus.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.